Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
17 Maio 2022 - 9:00AM
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
non-alcoholic steatohepatitis (NASH), announced today its
management team will participate in two upcoming investor
conferences:
H.C. Wainwright Global Life Sciences Conference
Fireside chat at 7:00 AM ET on Tuesday, May 24, 2022.
UBS Global Healthcare Conference Fireside chat
at 8:30 AM ET on Tuesday, May 24, 2022.
The presentations will be webcast and archived recordings will
be available for replay in the Investors & Media section of the
Madrigal website after the events.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
non-alcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s lead candidate, resmetirom, is a
once daily, oral, thyroid hormone receptor (THR)-β selective
agonist that is designed to target key underlying causes of NASH in
the liver. Resmetirom is currently being evaluated in two Phase 3
clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to
demonstrate multiple benefits in patients with NASH. For more
information, visit www.madrigalpharma.com.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024